The ChinaBio® Partnering Forum 2015 brought a record 858 internationally-focused life science executives and investors to Shanghai, China last week. The event, held April 15–16, is China’s premier life science partnering event for dealmakers interested in cross-border partnerships that will enable them to gain access to China’s rapidly growing healthcare market.

Global pharma companies were represented at the event, with executives in attendance from AstraZeneca, Bayer HealthCare, Johnson & Johnson Innovation, MSD, Novo Nordisk, Roche, and many others. In addition, 435 companies attended, with a record 50 innovative companies, organizations and researchers having presented their technologies or products in order to initiate strategic alliances at ChinaBio® Partnering Forum.

“As the second largest pharma market, China is a growing global force for the life science industry,” said Greg B. Scott, Founder of ChinaBio® Group. “Western companies of all sizes now clearly understand that they must have a presence in China, which in turn drives the increased demand for cross-border partnering, and is evidenced by the continued growth of ChinaBio® Partnering Forum, the largest global dealmaking event in China.”

The program presented panels relevant to cross-border dealmaking, and featured China and international life science executives including:

● Peter Corne, LLM – Managing Partner, Dorsey & Whitney LLP;
● Anand Gautam – Director, R&D Innovation Sourcing and Academic Partnerships, Novo Nordisk;
● Ajay Gautam, PhD, MBA – Executive Director and Head of Collaborations, AsiaPac and Emerging Markets, AstraZeneca;
● Ruediger Hermann – Partner, Corporate Life Sciences, Dechert LLP;
● Lewis Ho – Partner, Dechert LLP HK;
● Frank S. Hong, JD – Partner, Dorsey & Whitney LLC;
● Yuliang Huang, PhD – CEO, Generon (Shanghai) Corporation Ltd.;
● Judith Li, MBA – Principal, Lilly Asia Ventures;
● Geoffrey Lin, JD – Partner, Ropes & Gray LLP;
● Scott Liu, PhD – President and CEO, Henlius Biotech Co., Ltd.;
● Mark G. Lotter, MBA – Founder and CEO, Nuance Biotech Inc.;
● Peter Luo, PhD – Founder and CEO, Adagene (Suzhou) Limited;
● Mark Noguchi, MBA – VP and Global Head, Alliance and Asset Management, Roche Partnering;
● Dianna Qian, MBA – Principal of Healthcare Team, FountainVest;
● Jonathan Wang, PhD, MBA – Senior Managing Director, OrbiMed Asia;
● Katherine Wang, LLM – Partner, Ropes & Gray LLP;
● Steve Yang, PhD – Executive VP and COO, WuXi AppTec;
● Michael Yu, PhD – President and CEO, Innovent Biologics, Inc.;
● Joe Zhou, PhD – CEO, Genor BioPharma and VP, Walvax Group; and
● Zhengying Zhu, MD, PhD – General Manager and Chief Medical Officer, Luoxin Pharmaceutical.

ChinaBio® Partnering Forum is co-organized by EBD Group, the premier partnering conference firm for the life science industry, and ChinaBio® Group, a leading consulting and advisory firm in Shanghai.

Panel videos and conference coverage will be available online at partnering360:Insight.

Disclosure: ChinaBio® Today is a publication of ChinaBio® Group.